Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVACROSS: Bevacizumab and XELOX in Rectal Adenocarcinoma
NCT00557713Phase 2Unknown
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in rectal adenocarcinoma. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT00557713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00557713.